Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TEK | Q02763 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 8/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1075382 | 0.90 | MAP2K1 (0.43) | MAPTGAATHRBTEKMAP2K1 | |
| SCHEMBL8059139 | 0.89 | MAP2K1 (0.43) | MAPTGAATHRBL3MBTL1NR4A2 | |
| SCHEMBL3886544 | 0.88 | MEN1 (0.45) | MAP2K1MEN1KMT2AGFERSMN1; SMN2 | |
| SCHEMBL1078430 | 0.86 | CYP2C9 (0.45) | GAANR4A2MEN1KMT2ANPC1 | |
| SCHEMBL8059115 | 0.85 | MKNK1 (0.40) | L3MBTL1NR4A2KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL1077501 | 0.84 | MAPT (0.41) | MAPTGAATHRBTEKNR4A2 | |
| SCHEMBL1040419 | 0.81 | MEN1 (0.56) | MAP2K1MEN1KMT2AEGFRABCB11 | |
| SCHEMBL5990169 | 0.79 | MEN1 (0.43) | MAP2K1MEN1KMT2AGFERSMN1; SMN2 | |
| SCHEMBL4545994 | 0.78 | MAPT (0.43) | MAPTMEN1KMT2AGFERSMN1; SMN2 | |
| SCHEMBL5988682 | 0.78 | MEN1 (0.45) | MAP2K1MEN1KMT2AMAPK1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3000810-B1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVE AS MEK INHIBITOR | ARRAY BIOPHARMA INC (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-1663210-B1 | BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-3000810-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVE AS MEK INHIBITOR | Array Biopharma, Inc. (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2275102-B1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-8513293-B2 | Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal | ARRAY BIOPHARMA INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2130536-B1 | N3 alkylated benzimidazole derivatives as mek inhibitors | ARRAY BIOPHARMA INC (US) | 2013-05-08 | — | — | EP | disclosed |
| EP-2130537-B1 | N3 alkylated benzimidazole derivatives as mek inhibitors | ARRAY BIOPHARMA INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20120277277-A1 | Methods of Treating a Hyperproliferative Disorder or Inhibiting Cell Growth in a Mammal | ARRAY BIOPHARMA INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-8193231-B2 | Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193229-B2 | Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20070299063-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-7235537-B2 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1663210-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1482932-A4 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050143438-A1 | N3 alkylated benzimidazole derivatives as MEk inhibitors | ALEXION PHARMA INTERNATIONAL OPERATIONS LIMITED (IE) | 2005-06-30 | — | — | US | disclosed |
| WO-2005023251-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| EP-1482932-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040116710-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ASTRAZENECA AB (SE) | 2004-06-17 | — | — | US | disclosed |
| US-20030232869-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ASTRAZENECA AB (SE) | 2003-12-18 | — | — | US | disclosed |
| WO-2003077914-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277277-A1 | Methods of Treating a Hyperproliferative Disorder or Inhibiting Cell Growth in a Mammal | PCNA, MKI67, HRAS | MAPT 4275/4885GAA 454/4885THRB 2326/4885 |
| US-20030232869-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | CCNI, BRAF, CDK2 | MAPT 4763/4885GAA 3150/4885THRB 1665/4885 |
| US-20050143438-A1 | N3 alkylated benzimidazole derivatives as MEk inhibitors | BRAF, CCNI, NRAS | MAPT 4838/4885GAA 3646/4885THRB 1717/4885 |
| US-20070299063-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | BRAF, CCNI, NRAS | MAPT 4844/4885GAA 3576/4885THRB 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.